Abstract
Aim To investigate the impact of the COVID-19-pandemic on antidiabetic drug initiation
Methods Using Swedish national health registers, an interrupted time series study for all first-time dispensed antidiabetic drugs was performed. A minimum 14-month washout period was used. We calculated monthly cumulative incidence of antidiabetic drug initiations per 1000 population and estimated trends before and after the onset of the pandemic using segmented regression analysis.
Results Among 167,889 participants between 1Mar2019 and 30Nov2021, male sex (53%), age 18-64 (55.3%), unmarried status (52.5%), upper secondary education level (46.2%), and being employed (53.5%) were the most frequent characteristics. Mar2020, there was an immediate level drop in antidiabetic drug initiation (β2=-0.087%, P=0.01); however, the trend exhibited a rapid increase thereafter. Significant immediate level drops were identified for DPP4i (−0.087%, P=0.01), GLP1a (−0.008%, P=0.01) and SGLT2i (−0.033%, P=0.003). Older people (≥65) showed the largest immediate drop for antidiabetic drug initiation (−0.272%, P=0.003). SGLT2i demonstrated an increasing pattern both before and after the pandemic while metformin did reveal an increasing pattern among patients ≥65 years old after the pandemic.
Conclusion The results identified an immediate level drop at the onset of the pandemic for any antidiabetic drug initiation, but the trend increased rapidly thereafter.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research has ethics approval from the Swedish Ethical Review Authority (2020-01800 with subsequent amendments)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
NK: (nataliia.khanyk{at}farmaci.uu.se), FN: (fredrik.nyberg.2{at}gu.se), BW: (bjorn.wettermark{at}farmaci.uu.se), HL: (huiqi.li{at}gu.se), KEO: (katarina.eeg-olofsson{at}vgregion.se), SG: (soffia.gudbjornsdottir{at}medic.gu.se), MHH: (hossein.hajiebrahimi{at}farmaci.uu.se)
Data Availability
The data underlying this article cannot be shared publicly due to their containing sensitive information that could compromise the privacy of research participants. Analysis data will be shared upon reasonable request to the authors. Access to similar data requires permission. Apart from ethical approval from the Swedish Ethical Review Authority, researchers will also need approval from each register holder.
